Medical News Today logo Medical News Today 4 weeks ago

Bristol-Myers Squibb And ZymoGenetics Present Final Phase 1b Results For PEG-Interferon Lambda In Hepatitis C

Main Category: Liver Disease / Hepatitis Also Included In: Clinical Trials / Drug Trials Article Date: 03 Nov 2009 - 4:00 PST email to a friend printer friendly view / write opinions rate article Bristol-Myers Squibb Company (NYSE: BMY) and... Full Article at Medical News Today

Related Topics:

  1. ZymoGenetics, Inc.
  2. Bristol-Myers Squibb
  3. NASDAQ

Related Articles

  1. Drugs.com logo
    Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG-Interferon Lambda in Hepatitis C
    1 month ago

    Antiviral activity seen at all dose levels tested Results support moving to dose-ranging Phase II studies in treatment-naïve HCV patients PRINCETON, N.J. & SEATTLE--(BUSINESS WIRE)--Oct 31, 2009 - Bristol-Myers Squibb Company (NYSE: BMY) and... Full Article at Drugs.com

  2. Medical News Today logo
    ZymoGenetics Initiates Phase 2 Clinical Trial Of PEG-Interferon Lambda In Hepatitis C With Bristol-Myers Squibb
    1 month ago

    Main Category: Liver Disease / Hepatitis Also Included In: Clinical Trials / Drug Trials Article Date: 29 Oct 2009 - 0:00 PDT email to a friend printer friendly view / write opinions rate article ZymoGenetics, Inc. Full Article at Medical News Today

  3. Freshnews.com logo
    ZymoGenetics Initiates Phase 2 Clinical Trial of PEG-Interferon lambda in Hepatitis C with Bristol-Myers Squibb
    1 month ago

    SEATTLE -- (BUSINESS WIRE) -- ZymoGenetics, Inc. Full Article at Freshnews.com

  4. Medidata Solutions Extends Contract With Bristol-Myers Squibb
    1 month ago

    Medidata Solutions has reported a multi-year contract extension with Bristol-Myers Squibb for use of Medidata Grants Manager, an investigator site tool that helps sponsors ensure fair and consistent investigator payments, mitigate compliance risks and... Full Article at Pharmaceutical Business Review

View all Related Articles »

Related Quotes

  1. There is a strong need for additional options for hepatitis C patients
    – Brian Daniels SOURCE: Medical News Today 4 weeks ago
  2. There is a strong need for additional options for hepatitis C patients
    – Brian Daniels SOURCE: PR-Inside.com 1 month ago
  3. This study represents an important first step in addressing an unmet medical need, as this is one of the first comparative studies to evaluate the safety and efficacy of antiviral therapy in this difficult-to-treat patient population
    SOURCE: Freshnews.com 1 month ago
  4. Bristol-Myers Squibb is pleased to partner with ZymoGenetics in the development of this promising new investigational interferon
    SOURCE: Freshnews.com 2 months ago
View all Related Quotes »
(What's this?)
  1. Are you a Publisher?

    We built Daylife.com using our SmartMedia Services platform, which can give you thousands of content-rich, advertiser-friendly pages (like this one) on any topic and with full editorial control. Learn More »

    Our Customers
    prev
    next
  2. Our Products
    Daylife Select

    A point & click tool to create dynamic content portals. Learn More »

  3. Daylife API

    Unlimited smart, customizable content to suit any publisher. Learn More »

  4. Enterprise API

    Use the Daylife Platform to distribute content across your sites. Learn More »

  5. SmartContext

    Weave the web's best content into your own. Learn More »

Browse More Photos

Daylife is the web's largest archive of news photos

  1. FILE- In this Sept. 23, 2009 file photo, a technician works at the Medarex Inc. production facility in Bloomsbury, N.J. New York based drug maker Bristol-Myers Squibb Co. announced on Wednesday, July 22, 2009 that it is buying the Princeton, N.J. based company for about $2.1 billion in cash.

Cast of Characters

  1. ZymoGenetics, Inc.
  2. Bristol-Myers Squibb Bristol-Myers Squibb
  3. NYSE NYSE
  4. NASDAQ NASDAQ
  5. Brian Daniels
  6. Amylin Pharmaceuticals, Inc. Amylin Pharmaceuticals, Inc.